These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397 [TBL] [Abstract][Full Text] [Related]
4. Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling. Zhao J; Leonard C; Gemsenjäger E; Heitz PU; Moch H; Odermatt B Oncol Rep; 2008 Feb; 19(2):329-37. PubMed ID: 18202778 [TBL] [Abstract][Full Text] [Related]
5. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653 [TBL] [Abstract][Full Text] [Related]
6. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527 [TBL] [Abstract][Full Text] [Related]
7. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974 [TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Cho Mar K; Eimoto T; Tateyama H; Arai Y; Fujiyoshi Y; Hamaguchi M Histopathology; 2006 Feb; 48(3):286-94. PubMed ID: 16430475 [TBL] [Abstract][Full Text] [Related]
9. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM; Ibrahim TR Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma. Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712 [TBL] [Abstract][Full Text] [Related]
13. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Weinberger PM; Adam BL; Gourin CG; Moretz WH; Bollag RJ; Wang BY; Liu Z; Lee JR; Terris DJ Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):503-10. PubMed ID: 17515507 [TBL] [Abstract][Full Text] [Related]